NCT05530096 Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD
| NCT ID | NCT05530096 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sir Mortimer B. Davis - Jewish General Hospital |
| Condition | Multiple Myeloma |
| Study Type | OBSERVATIONAL |
| Enrollment | 70 participants |
| Start Date | 2024-05-01 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 70 participants in total. It began in 2024-05-01 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose : Detect and profile Multiple myeloma Measurable Residual Disease(MRD) prognostics for monitoring post-transplant Multiple Myeloma (MM) Patients receiving maintenance therapy.
Eligibility Criteria
Inclusion Criteria: * Confirmed MM diagnosis * Transplant eligible patients in a first remission * Known MRD level detected by ClonoSeq (other IMWG recognized methodologies can be also employed) * Availability of deidentified patient's demographic and clinical follow up data * Receiving standard of care treatment * Able to provide informed consent Exclusion Criteria: * Failure to meet inclusion criteria
Contact & Investigator
Rayan Kaedbey
PRINCIPAL INVESTIGATOR
Sir Mortimer B. Davis - Jewish General Hospital
Frequently Asked Questions
Who can join the NCT05530096 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Myeloma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05530096 currently recruiting?
Yes, NCT05530096 is actively recruiting participants. Contact the research team at rayan.kaedbey.med@ssss.gouv.qc.ca for enrollment information.
Where is the NCT05530096 trial being conducted?
This trial is being conducted at Montreal, Canada.
Who is sponsoring the NCT05530096 clinical trial?
NCT05530096 is sponsored by Sir Mortimer B. Davis - Jewish General Hospital. The principal investigator is Rayan Kaedbey at Sir Mortimer B. Davis - Jewish General Hospital. The trial plans to enroll 70 participants.